PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Files An 8-K Other Events
Item 8.01. Other Events.
announcing advancement in discussions with Sosei Corporate
Venture Capital Ltd. (Sosei CVC) towards establishing a new
corporation to pursue the clinical development and
commercialization of Pluristems PLX-PAD cell therapy product in
Japan. The registrant and Sosei CVC currently anticipate
definitive agreements are to be finalized in the coming months,
rather than by March 31, 2017 as previously announced.
incorporated herein by reference.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release dated March 30, 2017.
|
statements within the meaning of the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995 and
federal securities laws. These forward-looking statements
include, but are not limited to, those statements regarding the
establishment of a Japanese new corporation, the registrant and
Sosei CVCs plan to enter into definitive agreements and the
proposed timing of execution of such agreements. The registrant
may not be successful in negotiating definitive documentation by
the time period expected or at all, and even if successful, the
sale of securities may not be completed if the conditions to
closing such sale are not met. These forward-looking statements
and their implications are based on the current expectations of
the management of the registrant only, and are subject to a
number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. The forward-looking statements
contained in this Current Report on Form 8-K are subject to risks
and uncertainties, including those discussed in the registrants
reports filed from time to time with the SEC. Except as otherwise
required by law, the registrant undertakes no obligation to
publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
About PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI)
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases. PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) Recent Trading Information
PLURISTEM THERAPEUTICS INC. (NASDAQ:PSTI) closed its last trading session up +0.01 at 1.21 with 90,075 shares trading hands.
